We are live on ! Find out more
BA

Boston Advisors Portfolio holdings

AUM $1.91B
1-Year Est. Return 6.26%
This Fund
S&P 500
This Quarter Est. Return
+5.39%
1 Year Est. Return
+6.26%
3 Year Est. Return
+73.82%
5 Year Est. Return
+112.87%
10 Year Est. Return
AUM
$4.05B
AUM Growth
+$38.8M
Cap. Flow
-$116M
Cap. Flow %
-2.87%
Top 10 Hldgs %
18.39%
Holding
733
New
60
Increased
226
Reduced
298
Closed
60

Top Sells

Rank Stock Value
1
CLX icon
Clorox
CLX
+$24.7M
2
DIS icon
Walt Disney
DIS
+$19.9M
3
TGT icon
Target
TGT
+$19M
4
DRI icon
Darden Restaurants
DRI
+$18.6M
5
CI icon
Cigna
CI
+$17.6M

Sector Composition

Rank Sector Weight
1 Healthcare 17.77%
2 Technology 14.35%
3 Financials 11.2%
4 Industrials 10.03%
5 Communication Services 9.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SMG icon
126
ScottsMiracle-Gro
SMG
$3.97B
$10M 0.25%
+120,300
New +$9.49M
ALK icon
127
Alaska Air
ALK
$5.27B
$9.96M 0.25%
151,207
+53,822
+55% +$3.54M
SPGI icon
128
S&P Global
SPGI
$122B
$9.79M 0.24%
+77,315
New +$9.29M
JCP
129
DELISTED
J.C. Penney Company, Inc.
JCP
$9.75M 0.24%
1,057,910
-1,100
-0.1% -$10.5K
AIV
130
Aimco
AIV
$383M
$9.72M 0.24%
1,588,800
-38,990
-2% -$235K
SBGI icon
131
Sinclair Inc
SBGI
$994M
$9.71M 0.24%
336,029
-22,717
-6% -$658K
SNA icon
132
Snap-on
SNA
$21.2B
$9.66M 0.24%
63,558
-15,541
-20% -$2.4M
LYB icon
133
LyondellBasell Industries
LYB
$19.5B
$9.6M 0.24%
118,991
-152,811
-56% -$11.8M
TXT icon
134
Textron
TXT
$15B
$9.47M 0.23%
238,167
+1,085
+0.5% +$42.7K
JAZZ icon
135
Jazz Pharmaceuticals
JAZZ
$16.2B
$9.41M 0.23%
77,493
-83,825
-52% -$11.3M
BAX icon
136
Baxter International
BAX
$13.8B
$9.38M 0.23%
197,171
-199,460
-50% -$9.41M
BXMT icon
137
Blackstone Mortgage Trust
BXMT
$2.52B
$9.34M 0.23%
317,009
-6,467
-2% -$187K
SYNH
138
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$9.33M 0.23%
209,315
+72,086
+53% +$3.13M
PEG icon
139
Public Service Enterprise Group
PEG
$38.6B
$9.33M 0.23%
222,805
-34,483
-13% -$1.52M
LSI
140
DELISTED
Life Storage, Inc.
LSI
$9.18M 0.23%
154,766
+140,807
+1,009% +$9.01M
GS icon
141
Goldman Sachs
GS
$302B
$8.97M 0.22%
55,644
+2,589
+5% +$421K
CFG icon
142
Citizens Financial Group
CFG
$30.3B
$8.66M 0.21%
350,365
-3,911
-1% -$89.9K
ISBC
143
DELISTED
Investors Bancorp, Inc.
ISBC
$8.37M 0.21%
697,150
+25,085
+4% +$291K
BBY icon
144
Best Buy
BBY
$18.5B
$8.31M 0.21%
217,768
-130,726
-38% -$4.59M
MHK icon
145
Mohawk Industries
MHK
$7.29B
$8.26M 0.2%
41,240
-39,870
-49% -$8.19M
TMO icon
146
Thermo Fisher Scientific
TMO
$214B
$7.99M 0.2%
50,259
-1,005
-2% -$155K
STOR
147
DELISTED
STORE Capital Corporation
STOR
$7.99M 0.2%
271,060
-26,855
-9% -$799K
GE icon
148
GE Aerospace
GE
$368B
$7.33M 0.18%
51,675
-92,213
-64% -$13.8M
EME icon
149
Emcor
EME
$35.4B
$7.28M 0.18%
122,030
-57,475
-32% -$3.18M
DD icon
150
DuPont de Nemours
DD
$18.7B
$7.25M 0.18%
55,225
-354
-0.6% -$47.2K

Similar funds

Boston Advisors's Q3 2016 Portfolio in Review

As of Q3 2016, Boston Advisors held 733 positions worth $4.05B, up 0.97% from $4.01B the previous quarter. Its ten largest holdings account for 18% of the portfolio.

Boston Advisors's Q3 2016 filing shows 60 new, 226 increased, 298 reduced and 60 closed positions. Its largest new stake was Vertex Pharmaceuticals: 188,245 shares worth $16.4M. The largest sale was Clorox, an estimated $24.7M.

By sector, the portfolio is most concentrated in Healthcare at 18% of assets, down from 18% a quarter earlier, followed by Technology and Financials.

  • Boston Advisors's largest Q3 2016 buy was Vertex Pharmaceuticals: 188,245 shares worth $16.4M.
  • Boston Advisors added most to AbbVie in Q3 2016, an estimated $27.2M increase.
  • Boston Advisors's biggest Q3 2016 reduction was Clorox, cutting an estimated $24.7M.
  • Boston Advisors fully exited Cadence Design Systems in Q3 2016, selling an estimated $14.4M.
  • Boston Advisors's ten largest holdings make up 18% of its $4.05B portfolio in Q3 2016.
  • Boston Advisors opened 60 new positions and closed 60 in Q3 2016.
  • Boston Advisors's portfolio value rose 0.97% quarter-over-quarter to $4.05B.

Based on Boston Advisors's 13F filing for Q3 2016, filed 25 Oct 2016.